Pharmaceutical Stocks

Pharmaceutical stocks have grown tremendously as medicine advances. With diseases like Covid-19, diabetes, liver disease and other illnesses affecting more and more of the population, pharmaceutical companies are racing to find cures – further advancing medicine and driving pharma stock prices higher.

Big Pharma corporations like AstraZeneca, Merck & Co., Pfizer, and Johnson & Johnson are leading the charge against the novel coronavirus, competing with smaller biotech names — such as Moderna and Novavax. The race to find a Covid-19 vaccine has sent both pharma and biotech stocks to the moon.

Abbott Labs Spinoff Looks Like the Right Move

By Barry Cohen, Health Care Writer
Shareholders would likely be better served by the company's prescription drug business standing alone. Here's why.

Why Eli Lilly Could Be a Lottery Stock Pick

By Barry Cohen, Health Care Writer
If Eli Lilly is successful in delaying the progression of Alzheimer’s disease with its experimental drug, it could make Lipitor look like a mid-sized product. The odds?

5 Small-Cap Buys With Large Potential

By Louis Navellier, Editor, Growth Investor
Small cap stocks can be very risky, but very rewarding. These 5 do everything from mining to groceries -- and they can deliver big profits.

10 Game-Changing Health Care Stocks to Buy

By Hilary Kramer, Editor, GameChangers
These 10 diverse stocks are likely to improve their earnings and stock prices in 2012. Take a look.

Top 5 Emerging Growth Stocks for December

By Louis Navellier, Editor, Growth Investor
Louis Navellier's top five emerging growth stocks for December include standouts such as Jazz Pharmaceuticals and Hansen Natural Corp.

Affymax Shares Hang on an FDA Decision

By Barry Cohen, Health Care Writer
Affymax's stock price is swinging wildly as investors await a ruling on the company's promising kidney disease drug.

Investors Still Must Pick Generic Drug Companies By Hand

By Barry Cohen, Health Care Writer
The high-risk generic drug sector still is without an ETF, leaving investors to weed out the pharmaceutical winners and losers for themselves.

Biogen Is in the Right Place at the Right Time

By Susan J. Aluise, Aviation, Auto & Transportation Writer
BIIB's promising multiple scerlosis drug BG-12 could be a huge winner, just when Novartis' entry is stumbling.

Onyx Pharma May See Suitors Lining Up

By Barry Cohen, Health Care Writer
The company's current and future drugs are likely attractive to larger companies faced with slowing growth.

Ranbaxy Closes In on FDA Approval for Generic Lipitor

By Barry Cohen, Health Care Writer
Ranbaxy could sell $650 million worth of the drug in its first 180 days. But Pfizer is battling hard to keep branded Lipitor alive.

Forget Amgen — Buy This Pharmaceutical Stock Instead

By Lawrence Meyers, InvestorPlace Contributor
Amgen is a world-class biotech company, but its big growth is a thing of the past. Another pharma stock is positioning itself for a place in your portfolio.

Questcor Earnings Could Soar 200% in Q4

By John Kmiecik, InvestorPlace Contributor
Will Santa Claus make a bullish appearance and pull this market out of its doldrums? Traders and investors shouldn’t count on it this year like…

Blood-Thinner Drug Race Is Still Wide Open

By Barry Cohen, Health Care Writer
The major pharmaceutical companies are hoping to supply the definitive treatments, but the medical community hasn't yet declared a winner.

Merck CEO Pledges Drug Pipeline Will Yield Results in Both Short and Long Term

By Barry Cohen, Health Care Writer
Merck CEO Kenneth Frazier acknowledges company's lagging stock, touts potential of numerous drugs in late development stages.

Pfizer’s Latest Gambit for Keeping Lipitor Alive

By Barry Cohen, Health Care Writer
Like a vampire refusing to die, Lipitor keeps on going. Now, PFE has a deal to sell the cholesterol-lowering drug directly to patients at generic cost.

Gilead’s Giant Gamble in Buying Pharmasset

By Barry Cohen, Health Care Writer
The $11B price tag raises the stakes big-time, and critics say Gilead is overpaying to get Pharmasset's promising hepatitis C treatment.

Stocks to Watch on Cancer Vaccines’ Huge Financial Potential

By Barry Cohen, Health Care Writer
These companies are making progress on new therapeutic cancer vaccines -- and success for any one of them could be huge for investors.

Big Pharma’s Emerging Markets Foray Hits Roadblocks

By Barry Cohen, Health Care Writer
Companies are finding plans for global expansion aren't without hiccups.

Bristol-Myers, AstraZeneca Diabetes Drug Gets New Hope

By Barry Cohen, Health Care Writer
Cleveland Clinic's positive review revitalizes Bristol-Myers, AstraZeneca's dapagliflozin, an experimental drug taking on a growing diabetes management market.
Load More